DaVita Inc. (NYSE:DVA) Position Trimmed by Jump Financial LLC

Jump Financial LLC trimmed its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 78.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,849 shares of the company's stock after selling 17,262 shares during the period. Jump Financial LLC's holdings in DaVita were worth $725,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Wellington Management Group LLP raised its position in shares of DaVita by 9.1% during the 4th quarter. Wellington Management Group LLP now owns 2,711 shares of the company's stock worth $405,000 after purchasing an additional 227 shares during the period. Franklin Resources Inc. lifted its stake in DaVita by 134.6% in the third quarter. Franklin Resources Inc. now owns 54,901 shares of the company's stock valued at $8,885,000 after buying an additional 31,502 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of DaVita by 201.7% during the fourth quarter. Assenagon Asset Management S.A. now owns 74,617 shares of the company's stock valued at $11,159,000 after acquiring an additional 49,885 shares during the period. Hussman Strategic Advisors Inc. grew its position in shares of DaVita by 200.0% during the fourth quarter. Hussman Strategic Advisors Inc. now owns 25,200 shares of the company's stock worth $3,769,000 after acquiring an additional 16,800 shares during the last quarter. Finally, Nordea Investment Management AB increased its holdings in shares of DaVita by 4.9% in the 4th quarter. Nordea Investment Management AB now owns 264,535 shares of the company's stock worth $39,712,000 after acquiring an additional 12,339 shares during the period. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Price Performance

NYSE:DVA opened at $134.95 on Wednesday. DaVita Inc. has a 52-week low of $130.96 and a 52-week high of $179.60. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The firm has a market cap of $10.80 billion, a P/E ratio of 12.57, a PEG ratio of 1.07 and a beta of 1.04. The business's 50-day moving average price is $147.51 and its 200 day moving average price is $155.64.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, sell-side analysts predict that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on DVA. StockNews.com raised DaVita from a "hold" rating to a "buy" rating in a report on Thursday, April 10th. Barclays increased their price target on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. Cowen restated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $166.33.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.